Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

10:16 EDT 22nd May 2018 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 31,000+ from Globe Newswire

Monday 21st May 2018

Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco

HASBROUCK HEIGHTS, N.J., May 22, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend. Dr. Ronald Tutrone of Chesapeake Ur...

ICC Labs Signs LOI to Export Cannabis to Germany for Medicinal Purposes

VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (“ICC Labs” or the “Company”) (TSX-V:ICC) (Frankfurt:2Q9) is pleased to announce that it has signed a letter of intent with CanPharma GmbH (“CanPharma”), a licensed importer and wholesaler of narcotics in the Federal Republic of Germany. Through its relationship with CanPharma, ICC Labs intends to export t...

BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board

RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock.  The offering closed on May 21, 2018, yielding net proceeds of $48.9 million to BDSI.    As previously announced, as part of t...

Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance

LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today announces it will be presenting two ...

Yield10 Bioscience Exercises Option with University of Missouri to Obtain Exclusive Worldwide License to Advanced Technologies for Oilseed Crops

WOBURN, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to achieve step-change improvements in crop yield to enhance global food security, today announced that it has executed an exclusive worldwide license to two novel gene technologies to boost oil content in crops from the University of Missouri (MU). The university previo...

Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) have been published online in JAMA Oncology.  The vast majority of men with CRPC have bone metastases. Bone scan is the standard im...

Zosano Appoints Steven A. Elms to Board of Directors

FREMONT, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Steven A. Elms, Managing Partner at Aisli...

Progressive Care Purchases TCGRx Pouch Packaging System to Add to Expanding Robot Pharmacy Machinery Fleet

MIAMI, May 22, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced that the company has purchased a new TCGRx Automated Pouch Packaging System for its Miami-Dade County PharmCo location, which is to be installed in the beginning of June 2018. Progressive Care’s wholly owned subsid

Incysus Moves Its Corporate Domicile to Delaware

NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to Delaware and changed its name to “Incysus Therapeutics, Inc.” William Ho, Chief Executive Officer of Incysus s...

Innovate Biopharmaceuticals Scheduled to Present at BIO 2018 Convention in Boston on Tuesday, June 5, 2018, at 4:45PM

RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, intends to present on larazotide for celiac disease at BIO 2018 in Boston on Tuesday, June 5th at 4:45pm ET in Theater 2. About Innovate Biopharmaceuticals, Inc. (Nasda...

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6....

FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. ...

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic

SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) applic...

BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102

ANAHEIM, CA, May 22, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Health (NIH) to fund the development and study plans for BICX102, the Company’s sustained release naltrexone implant fo...

International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2018

CARLSBAD, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update announcing operating results for the three months ended March 31, 2018. “This...

Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

CHESTERBROOK, Pa., May 22, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced two presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting, held in Nashville, Tennessee, May 19-23. The first poster highlighted efficacy, safety and tolerability data from 115 colorectal patients from the ATHENA Phase 3 multicenter, open label safety...

OncoDNA announces screening collaboration with Kura Oncology

- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE NEWSWIRE) -- OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, is pleased to announce that it has signed a screening agreement with Ku...

Abattis Bioceuticals Announces Release of New Line of Vaporizers

VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce the addition of three new vaporizers to its product line. Since the Company’s acquisition of Green Tree Therapeutics (“Green Tree”) earlier this year, Abattis has been working to expand its retail presence and product line and ...

Avivagen Announces Drawdown from Credit Facility

OTTAWA, May 22, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTCPink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces it has drawn down CAD $800,000 from the cred...

Draft resolutions of the Annual General Meeting of Shareholders of JSC „Olainfarm” to be held on June 05th, 2018

Draft resolutions of the Annual General Meeting of Shareholders of JSC „Olainfarm” to be held on June 05th, 2018: 1. Report of the Board on results of operations in 2017.Draft resolution:  To take notice of the Report of the Board of the JSC “Olainfarm” on results of operations in 2017. 2. Report of the Council on results of operations in 2017.Draft resolution: To take notice of th...

Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute

CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Nature Communications demonstrating the anti-cancer potential of ALRN-6924 in models of T-cell lymphoma (TCL). ALRN-6924 is designed to reactivate p53-mediated tu...

Sensorion Appoints Professor Christine Petit, MD, PhD as Chair of its Scientific Advisory Board

Internationally-renowned geneticist and neurobiologist with decades of hearing research leadership to head Sensorion’s Scientific Advisory Board MONTPELLIER, France, May 22, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that Professor Christine Petit, M.D., Ph.D. will be appointed as the Ch...

MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

NEWS RELEASE Moderated posters and oral presentations feature clinical and health economic validations of SelectMDx, ConfirmMDx and prospective clinical validation of AssureMDx IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, May 22, 2018 - MDxHealth SA (Euronext: MDXH.BR) announces that significant data on the performance of its SelectMDx, and ConfirmMDx tests for prostate cancer and ...

Sunday 20th May 2018

Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer

CHESTERBROOK, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced the appointment of Mark Demitrack, M.D., as Senior Vice President and Chief Medical Officer.  Dr. Demitrack brings over 20 years of industry experience at large and small biopharmaceutical companies where he has led numerous CNS programs pre- and post-approval.  “Mark is a highly experienced ph...

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD

LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today presented Phase 2a and pharmacokinetic data from two clinical trials evaluating its lead product candidate, RPL554, in chronic obstr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks